Supportive care

Filgrastim versus TBO-filgrastim to reduce the duration of neutropenia after autologous hematopoietic stem cell transplantation: TBO, or not TBO, that is the question. Trifilio S et al. Clin Transplant. 2015 Oct 22. doi: 10.1111/ctr.12637. [Epub ahead of print]. Surgery for vertebral involvement in Multiple Myeloma. Donnarumma P et al. J Neurosurg Sci. 2015 Oct 16. [Epub ahead of print]. Effectiveness of Haemodiafiltration…

Complications of myeloma and its treatments

Endobronchial plasmacytoma in patient with multiple myeloma. Sunnetcioglu A et al. Clin Respir J. 2015 Oct 27. doi: 10.1111/crj.12408. [Epub ahead of print]. Rapid Progression of Vascular and Soft Tissue Calcification while Being Managed for Severe and Persistent Hypocalcemia Induced by Denosumab Treatment in a Patient with Multiple Myeloma and Chronic Kidney Disease. Ueki K et al. Intern Med. 2015;54(20):2637-42. doi: 10.2169/internalmedicine.54.4946. Epub 2015…

Current treatments

Sequential versus alternating administration of VMP and Rd in elderly patients with newly diagnosed MM. Mateos MV et al. Blood. 2015 Oct 23. pii: blood-2015-08-666537. [Epub ahead of print]. Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma. Cavo M et al. Leukemia. 2015 Oct 7. doi: 10.1038/leu.2015.274. [Epub ahead of print].…

Diagnostic tests and prognostic indicators

MicroRNAs in urine are not biomarkers of multiple myeloma. Sedlaříková L et al. J Negat Results Biomed. 2015 Sep 23;14(1):16. Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma. Besse L et al. PLoS One. 2015 Sep 21;10(9):e0137294. doi: 10.1371/journal.pone.0137294. Higher Decorin Levels in Bone Marrow Plasma Are Associated with Superior Treatment Response to Novel Agent-Based Induction in Patients with Newly…

Emerging treatments

A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple Myeloma. Rosenthal A et al. Br J Haematol. 2015 Sep 25. doi: 10.1111/bjh.13765. [Epub ahead of print]. Carfilzomib, pomalidomide, and dexamethasone (CPD) in patients with relapsed and/or refractory multiple myeloma. Shah JJ et al. Blood. 2015 Sep 17. pii: blood-2015-05-643320. [Epub ahead of print].…

Biology and genetics

Epigenetic silencing of a long non-coding RNA KIAA0495 in multiple myeloma. Wong KY et al. Mol Cancer. 2015 Sep 26;14(1):175. 3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myeloma. de la Puente P et al. Biomaterials. 2015 Sep 12;73:70-84. doi: 10.1016/j.biomaterials.2015.09.017. [Epub ahead of print] Transcriptional dysregulation of the deleted in colorectal carcinoma gene in multiple…

General

Myeloma escape from immunity: an “inside” job. Rapoport AP. Blood. 2015 Sep 17;126(12):1401-3. doi: 10.1182/blood-2015-07-659490. Antibody based immunotherapy for multiple myeloma: It’s about time. Sher T et al, Leuk Lymphoma. 2015 Sep 16:1-17. [Epub ahead of print]. Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies. Karp Leaf R et al. Curr Hematol Malig Rep. 2015 Sep 4. [Epub ahead of…